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It is well admitted that the link between chronic inﬂammation and cancer involves cytokines and mediators of inﬂammatory
pathways, which act during the diﬀerent steps of tumorigenesis. The cyclooxygenases (COXs) are a family of enzymes, which
catalyze the rate-limiting step of prostaglandin biosynthesis. This family contains three members: ubiquitously expressed COX-
1, which is involved in homeostasis; the inducible COX-2 isoform, which is upregulated during both inﬂammation and cancer;
and COX-3, expressed in brain and spinal cord, whose functions remain to be elucidated. COX-2 was described to modulate
cell proliferation and apoptosis mainly in solid tumors, that is, colorectal, breast, and prostate cancers, and, more recently, in
hematological malignancies. These ﬁndings prompt us to analyze here the eﬀects of a combination of COX-2 inhibitors together
withdiﬀerent clinically used therapeutic strategies in order to further improve the eﬃciency of futureanticancer treatments. COX-
2 modulation is a promising ﬁeld investigated by many research groups.
1.Introduction:Inﬂammationand
Cancer areLinked
Inﬂammationisthemajorreactionofnaturalimmunitywith
the goal to defend the organism against pathogens. It can be
induced upon bacterial infections by compounds including
lipopolysaccharides, as well as by viruses, which are detected
by Toll-like receptors (TLRs), expressed by immune cells
like macrophages. Besides, inﬂammation can be triggered
by physical injuries (i.e., UV) or chemical compounds (i.e.,
reactive oxygen species) [1]. The activation of speciﬁc recep-
tors triggers intracellular signals (i.e., NFκB, p38, or MAPKs-
mediated),whichregulatepro-inﬂammatorycytokineexpre-
ssion,suchasinterleukin1beta(IL1β),tumornecrosisfactor
alpha (TNFα), interleukin 6 (Il6), together with chemokines
and cell adhesion proteins [1], in turn, leading to the
recruitment and the activation of immune cells.
Several diseases are associated to chronic inﬂamma-
tion, such as osteoarthritis, Crohn’s disease, and cancer
[2]. Although the ﬁrst evidence of a connection between
inﬂammation and cancer dates back to more than a century
ago [3], only recently, this link has been further investigated,
thus evidencing that the incidence of several cancers is
tightly associated to inﬂammation such as colon, breast, and
prostate cancers [4–6]. This hypothesis is supported by the
ﬁndings that the tumor microenvironment is characterized
by the inﬁltration with diﬀerent types of immune cells (i.e.,
dendritic cells, lymphocytes, and macrophages) responsible
for the release of cytokines [1]. The role of these cytokines
in tumor incidence has been established in many studies.
For example, the overexpression of TNFα in transgenic
mice bearing a lung tumor is associated with an increase
of the size of the tumor [7]. Moreover, a chronic intake
of nonsteroidal antiinﬂammatory drugs (NSAIDs) leads to
a signiﬁcant reduction in the incidence of such tumors.
Colorectal cancer (CRC), which remains an important cause
of death in the industrialized world, is one of the most
characterized types of tumor that beneﬁts from treatment by
NSAIDs [8]. Interestingly, chronic use of aspirin is reported
to reduce the relative risk of CRC by about 50% [9]. Familial
adenomatous polyposis, an inherited form of colon cancer,
is characterized by the development of preneoplastic polyps.2 International Journal of Cell Biology
At the molecular level, this disease is caused with a mutation
of a tumor suppressor gene called Adenomatous polyposis
coli (APC). It has been shown that the use of NSAIDs, like
sulindac, as a chemopreventive treatment, is able to decrease
the incidence of polyp formation [10]. Similar results were
obtained with celecoxib [11], which is now approved by the
Food and Drug Administration’s Oncologic Drugs Advisory
Committee as an adjuvant in FAP therapy.
A body of evidence indicates a role for inﬂammation
in the development/modulation of diﬀerent steps of cancer
progression. Inﬂammation may play a role in tumor initia-
tion by triggering the production of reactive oxygen species
(ROS), responsible for DNA damage, thus increasing the
rate of mutations [12]. It may also be implicated in tumor
promotion, where inﬂammation triggers the secretion of
growth factors, such as the epithelial (EGF) and ﬁbroblast
growth factors (FGF). These, in turn, favor the proliferation
ofinitiatedtumorcellsbydetermininganimbalancebetween
cell proliferation and cell death stimuli [6], due to the
activation of diﬀerent cell survival pathways [7].
Besides, the diﬀerent cytokines produced during inﬂam-
mation (i.e., TNFα,I L 1 β, IL6, and IL8) can also activate
several survival pathways, thus leading to an escape of tumor
cells from cell death. Well known is the case of TNFα,
produced by tumor and immune cells, which leads to the
survival of cancer cells by the upregulation of antiapoptotic
proteins, that is, Bcl-2 [13–15], via the activation of the
nuclear factor kappa B (NFκB) [16]. The modulation of
pro-survival pathways or anti-apoptotic proteins makes the
expression/activation of such proinﬂammatory mediators
also a determining factor in chemoresistance. A constitu-
tive activation of such proinﬂammatory factors has been
frequently found in many cancers, such as hepatocellular
carcinoma [17], prostate cancer [18], as well as chronic and
acutemyeloidleukemia[19],whereitisfrequentlyassociated
with a bad prognosis. In these instances, the modulation
of Bcl-2 anti-apoptotic family members has been frequently
shown [13–15, 20].
Amongst the diﬀerent mediators of inﬂammation, the
cyclooxygenases (COXs) clearly appear to be implicated in
cancer. This review focuses on COX-2, the inducible form,
normally induced and implicated in inﬂammation, and
intends to analyze what is currently known about the link
between COX-2 and cancer, in terms of eﬀects on cell pro-
liferation and cell death. In this view, we will focus our
attentiononstudiesanalyzingtheeﬀectsofCOX-2inhibitors
on cancer cells, when used alone as well as in combination
with therapeutic approaches, including radiotherapy, chem-
otherapeutic agents, and photodynamic therapy. Finally, we
will consider the relevance of COX-2-independent eﬀects.
2. The CyclooxygenaseEnzyme Family
Cyclooxygenases (or prostaglandin H synthases), commonly
referred to as COXs, are a family of myeloperoxidases located
at the luminal side of the endoplasmic reticulum and nuclear
membrane [21], which catalyze the rate-limiting step of
prostaglandinbiosynthesisfromarachidonicacid[21].These
enzymes act by two coupled reactions. The ﬁrst one is the
conversion of arachidonic acid released from the plasma
membrane by phospholipase A2 to prostaglandin G2 by
the cyclooxygenase activity. The second reaction is mediated
by the peroxidase activity and leads to the conversion
of prostaglandin G2 to prostaglandin H2. Then, diﬀerent
synthases convert prostaglandin H2 to prostaglandin D2,
F2α, E2, I2, and thromboxane A2 (Figure 1).
Prostanoids (prostaglandins and thromboxanes) are
immediately released from the cells, where it is believed
that they act locally in an autocrine and paracrine manner
through diﬀerent receptors activating diﬀerent intracellular
pathways still to be completely elucidated (Figure 1)[ 22].
Prostaglandins, speciﬁcally, are important for physiological
functions like vasodilatation (PGD2, PGE2, PGI2), gastric
cytoprotection (PGI2), maintenance of renal homeostasis,
and platelet aggregation. Besides, prostaglandins play a
major role in mediating fever (PGE2), pain sensitivity, and
inﬂammation [21].
So far, three isoforms of COXs have been identiﬁed.
Cyclooxygenase-1(COX-1)isaglycoproteinof71kDa,which
is constitutively expressed in diﬀerent tissues. COX-1 is
encodedbyageneonchromosome9andplaysaroleintissue
homeostasisbymodulatingseveralcellularprocessesranging
fromcellproliferationtoangiogenesisorplateletaggregation
due to thromboxane production [21].
Cyclooxygenase-2 (COX-2) is the inducible isoform,
which is regulated by growth factors and diﬀerent cytokines
such as IL1β,I L 6 ,o rT N F α [23], therefore overexpressed
during inﬂammation. The COX-2 gene is located on chro-
mosome 1 and its promoter displays an NFκBr e s p o n s e
element as well as other cytokine-dependent (i.e., IL6)
response elements [21]. The protein shows a 60% homology
with COX-1 [24]; in addition, COX-2 presents a C-terminal
extension and a diﬀerent binding site for NSAIDs, which
makes COX-2 a preferential target compared to COX-1, thus
being speciﬁcally inhibited at lower doses [25].
Finally, COX-3 has been identiﬁed as a splice variant of
COX-1, and it is present mainly in brain and spinal cord
[26, 27]. Currently, the role of COX-3 is not known. Some
pieces of evidence suggest a possible role in pain sensitivity,
based on studies focused on the mechanism of action of
acetaminophen (paracetamol), recently evoked as a selective
inhibitor of COX-3 [28]. However, this hypothesis is debated
because other ﬁndings argue that acetaminophen targets at
the same time COX-2 [29].
3. COX-2 As a Tumor Promoter and a Good
Candidatefor Cancer Therapy
Overexpression of COX-2 has been detected in a number
o ft u m o r s ,s u c ha sc o l o r e c t a lb r e a s ta sw e l la sp a n c r e a t i c
and lung cancers [2, 30–32], where it correlates with a
poor prognosis. Moreover, overexpression of COX-2 has
been reported in hematological cancer models such as
RAJI (Burkitt’s lymphoma) and U937 (acute promonocytic
leukemia) [33, 34]a sw e l la si np a t i e n t ’ sb l a s tc e l l s[ 32, 34].
Data suggested that COX-2 may play a role in diﬀerent steps
of cancer progression, by increasing proliferation of mutated
cells [30], thus favoring tumor promotion as well as byInternational Journal of Cell Biology 3
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Figure 1: Metabolism of arachidonic acid by COX-2 and receptors implicated in response to prostaglandins (according to Chandrasekharan et
al. [21]). Prostaglandins act through diﬀerent receptors to mediate their eﬀects. PGE2 is able to bind four receptors (EP1, 2, 3, and 4). These
receptors do not possess the same ligand aﬃnity and their expression is tissuedependent. The diﬀerent receptors are associated with diﬀerent
intracellular pathways. Most of these receptors are localized in the plasma membrane but nuclear receptors PPARγ can also bind PGJ2.
Abbreviation: COX-2, cyclooxygenase-2; PG, prostaglandin; FP, prostaglandin F receptor; DP, prostaglandin D receptor; EP, prostaglandin E
receptor; IP, prostaglandin I receptor; PPAR, peroxisome proliferator-activated receptor; NSAIDs, nonsteroidal anti-inﬂammatory drugs.
aﬀecting programmed cell death and aﬀecting the eﬃcacy
of anticancer therapies [35–39] to be, ﬁnally, implicated in
metastasis formation, for example, by aﬀecting apoptosis
induced by loss of cell anchorage (anoikis) [40].
COX-2 induction or overexpression is associated with an
increased production of PGE2, one of the major products of
COX-2 which is known to modulate cell proliferation, cell
death, and tumor invasion in many types of cancer including
colon, breast, and lung. Prostaglandin E2 acts through
diﬀerent membrane receptors called EP receptors (EP1, EP2,
EP3, and EP4) [41] .T h e s er e c e p t o r sa r ea l ll o c a t e do n
the cell surface and characterized by seven-transmembrane
domains, and rhodopsin-type G protein-coupled receptors,
but trigger diﬀerent signaling pathways. Thus, it is known
that EP1 signaling acts through phospholipase C/inositol
triphosphate signaling, leading to intracellular mobilization
of calcium. EP2 and EP4 receptors are coupled with G
proteins which activate adenylate cyclase, leading to an
increase of intracellular cAMP [41]. cAMP is then able to
activate kinases such as protein kinase A (PKA) or PI3K for
example,andalsoGSK3leadingtoanactivationofβ-catenin,
a pathway regulating cell proliferation [42, 43]. In contrary
to EP2 and EP4, EP3 is coupled with Gi protein, leading
to an inhibition of adenylate cyclase, and thus a decrease
of cAMP inside the cells [41]. The diﬀerential expression
of these diﬀerent receptors according to the cell type may
explain the diverse and antagonist eﬀects of PGE2 described
in literature.
Until now, there are multiple evidences about the role
of PGE2 in tumorigenesis in some cancers. These evidences
are mostly described for adherent tumors while this link
is poorly understood for hematopoietic malignancies such
as leukemia or lymphoma. Indeed, several papers have
reported that PGE2 is the most important prostaglandin
produced during colorectal carcinogenesis [44]. Moreover, it
is known that the level of PGE2 increases in a size-dependent
manner in Familial Adenomatous Polyposis (FAP) patients
[45], suggesting a correlation between tumor growth and
prostaglandin biosynthesis. Tumorigenesis is characterized
by a disequilibrium between cell proliferation and cell death.
PGE2 is able to inhibit apoptosis in human colon cancer
cells. It has been demonstrated that PGE2 can upregulate
the level of the anti-apoptotic protein Bcl-2 in HCA-7 cells
(adenocarcinoma), which produce signiﬁcant amounts of
PGE2. This paper described a modulation of the MAPK
pathway that precedes the upregulation of Bcl-2 [46]. PGE2
can mediate its eﬀect through EGF receptor, leading to
MAPK activation. The ability of PGE2 to modulate tumor
progression in colorectal cell has been shown in other
models of colon cancer such as HT-29 cells that express
EP receptors. In this cell type, PGE2 is associated with an
increase of cAMP through EP4 receptor. The eﬀect can be
reversed by L-161982, an antagonist of EP4 [47]. Moreover,
PGE2 transactivates EGFR by triggering the release of
amphiregulin, a well-known EGFR ligand [48]. SC-236, an
inhibitor of COX-2, is able to inhibit cell proliferation of
HT-29 cells and this eﬀect is greater in combination with an
amphiregulin neutralizing antibody [47]. In this cell line, the
expression of amphiregulin is correlated to the expression of
COX-2.4 International Journal of Cell Biology
The transactivation of EGFR by PGE2 can lead also to AKT
activation, which is a well-known survival pathway [49].
This eﬀect was well described in a study by Tessner et al.
[50] demonstrating that 16,16-dimethyl PGE2 (dmPGE2)
inhibits radiation-induced apoptosis in the mouse intestinal
epithelium. Using HCT-116 cell line as a model to reﬂect
the eﬀect on mouse small intestine, it has been shown
that the anti-apoptotic eﬀect of dmPGE2, which is known
to bind EP2, was tightly related to AKT phosphorylation
through activation of EGFR and leads to an inhibition of
Bax translocation in mitochondria, an important step for
apoptosis [51].
PGE2 modulates also tumor growth of lung cancer. This
eﬀect has been described by Yamaki et al. [52] showing
that PGE2 activates Src kinase in A549 cells, leading to
an induction of cell growth. These cells express EP3 that
activates Src (sarcoma) kinase. This study has demonstrated
that the activation of Src leads to an activating phosphory-
lation of STAT3, a transcription factor known to regulate
cyclin D1 transcription, an important positive regulator
of cell proliferation. Apoptosis can be inhibited because
STAT3 regulates the transcription of Bcl-XL, a well-known
anti-apoptotic protein [53]. Moreover, Src phosphorylates
p27, a protein known to inhibit cell cycle progression
especially at the G1/S transition [54]. However, it has been
recently shown that this protein plays a dual role as the
unphosphorylated form of p27 inhibits the cell cycle, and
thus cell proliferation. If phosphorylation occurs on T157
and T198 by PI3K (phosphoinositide 3-kinase), it triggers
cellcycletransitionbystabilizingthecyclinD1/cdk4complex
[55]. Thus phosphorylation of S10 appears to be important
forotherphosphorylation stepsandit hasbeenhypothesized
that Src kinase can play this role [55]. Moreover, it is
known that phosphorylation of p27 is responsible also for
its degradation by the proteasome [56]. All together these
data suggest that PGE2 increases cell proliferation via p27
phosphorylation through EP4 receptors.
Nonsmall lung cancer is characterized by a Ras mutation
correlatedwithapoorprognosis[57].ActivationofRasleads
to an upregulation of COX-2 resulting in increased PGE2
production [58]. PGE2 increases cell proliferation of A549
cells (adenocarcinoma) and this eﬀect is associated with an
activationofRaspathwayviaEP4receptor.Inthiscase,PGE2
mediates its eﬀect by the release of amphiregulin, the most
abundant ligand in A549 cells [59]. EGFR activation leads to
activation of MAPK pathway that regulates cell proliferation
by transactivating several oncogenes such as c-myc [60].
PGE2 is also important for tumor invasion. A study by
Ma et al. [61] described that PGE2 can increase the number
of metastasis. This eﬀect has been demonstrated in a model
in which murine mammary tumor cells 66.1 were injected
in syngenic immune competent BALB/CByJ mice. All these
cell lines express EP1, 2, 3, and 4. The use of EP4 antagonists
(AH23848 and AH6809) decreased surface tumor colonies
andreducedtumorinvasion.Anotherstudyhasrevealedthat
PGE2 increases the level of VEGF in granuloma [62]. VEGF
is an important factor of angiogenesis, and thus of tumor
progression by enhancing the vascularization of the tumors
[63].
Alltogether these data together suggest that PGE2 and,
thus, COX-2 play an important role in tumor progression
by enhancing cell proliferation, cell survival, and tumor
invasion. The diversity of PGE2 receptors and their diﬀerent
signaling pathways suggest that the protumorigenic eﬀect
of PGE2 depends on the cell type and the type of receptor
expressed. Until now, many signaling pathways associated
with tumor progression are linked to PGE2 and this could
explain why the use of COX-2 inhibitors is a good strategy
in cancer therapy. However, the signaling pathways of EP
receptors are not completely characterized and their precise
roles in the diﬀerent cancers remain to be elucidated before a
clinical application.
COXs may be targets of several compounds that may
inhibit their functions. Combination of such preferential or
selective COX-2 inhibitors with anti-cancer agents already
used in clinics were tested with the goal to improve the
eﬃciency of anti-cancer protocols.
COX-2 is the preferential target of several NSAIDs
(Figure 2)[64,65].Historically,NSAIDsusedforclinicaland
anti-inﬂammatory purposes were represented by the nonse-
lective COX-2 inhibitors, to which belong aspirin, sulindac
acidand,morerecently,agentssuchasnimesulide,ibuprofen
and naproxen. As their deﬁnition well reﬂects, this ﬁrst
generation of NSAIDs may aﬀe c tb o t hm a i nC O X si s o f o r m s ,
even if preferentially COX-2 (see above). Their mechanisms
of action are not all completely elucidated, complicated by
the fact that diﬀerent agents seem to act in diﬀerent ways.
For example, diﬀerent NSAIDs bind the active site of COX-
2. Commonly, binding occurs by a reversible competitive
inhibition (i.e., ibuprofen, naproxen, and indomethacin).
In contrast, aspirin is able to acetylate the active site of
COX at a serine residue, leading to an irreversible inhibition
(see Figure 2, summarizing the classiﬁcation of COX-2
inhibitors mentioned in this review). Considerable side
eﬀects generated by the interference with homeostatic func-
tions modulated by COX-1 include increased incidence of
gastrointestinal hemorrhage and ulceration upon chronic or
long-timeintake[66].AnovelgenerationofCOX-2-selective
inhibitors NSAIDs termed “Coxibs” was then developed.
These compounds promised to be much less gastrotoxic.
They act as competitive inhibitors of the active site of
COX-2 and present indeed a higher speciﬁcity. However,
concerns related to a long-time/chronic intake of these
drugs raised quite soon, following some clinical reports,
suggest a correlation between an increased risk of myocardial
infarction and their consumption [67]. This has lead to
the voluntary withdrawal of some of these agents, that is,
rofecoxib and valdecoxib [68], and drastic regulatory advices
regardingtheuseoftheotherones,thusopeningadiscussion
o nt h er e a lb e n e ﬁ t sv e r s u ss i d ee ﬀects of their use in clinics.
Consequently, studies focused on the use of traditional
versus COX-2-selective NSAIDs, frequently associated to the
elaboration of economical models, have been performed in
these latest years, with the aim to evaluate the real risks
together with the costeﬀectiveness and, possibly, identify
classesof users/patients whereregularNSAIDsintake maybe
beneﬁcial. Although, further analyses need to be performed,
a number of reports suggest that Coxibs may really increaseInternational Journal of Cell Biology 5
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Figure 2: COX-2 inhibitor classiﬁcation. COX-2 is the target of many compounds. COX-2 inhibitors described in this review are classiﬁed
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cardiovascular risks only in patients presenting a positivity
to other cardiovascular factor risks, as high blood pressure
and altered lipid metabolism [69–73]. These results suggest
that their use should be limited to patients with a low risk
of cardiovascular complications after analysis of multiple
biomarkers [Chaiamnuay et al., 2006, clinical reviews].
Therefore, the future perspective in the pharmacological
use of preferential versus selective COX-2 inhibitors is the
identiﬁcation of a panel of interesting biomarkers, helping
in deﬁning individual biological risk factors and limiting the
use of a speciﬁc class of COX-2 inhibitors to the appropriate
responders [74, 75]. This approach will have a considerable
implication in therapy as well as in chemoprevention of
inherited forms of colon cancer.
It is interesting to mention that recent alternative
approaches have been considered. Strillacci et al. [76]a n d
Chan et al. suggested RNA interference using adenoviral
vehicles. Moreover, other selective COX-2 inhibitors have
been developed and experimentally used: SC-558 [35],
DUP-697 [77], SC-58125 [78], and NS-398 [8]. Some of
them induce an irreversible inhibition. This is the case for
NS-398, which acts by inducing a conformational change
of COX-2 [25]( Figure 2). Another strategy discussed in
literaturecouldbetheuseofEPreceptorantagonists.Indeed,
it has been demonstrated that EP antagonists can decrease
cell proliferation and cell invasion [47, 61, 79]. This could be
a more speciﬁc strategy that could limit the other side eﬀects
of classic COX-2 inhibitors.
4. COX-2 As a Regulator of Cell Proliferation
Cell cycle is regulated by diﬀerent serine-threonine kinase
proteins called cyclin-dependent kinase (Cdk). These pro-
teins regulate the diﬀerent steps of cell cycle progression
by phosphorylating many substrates (i.e., nuclear lamins)
[54]. These proteins are regulated by phosphorylation and
dephosphorylation. Thus, Cdks can be activated by phos-
phatases such as CDC25C (cell division cycle 25 homolog
C) for CDK1 or kinase like CAK (Cdk activating kinase).
The activity of cdks is also regulated by cyclins, which form
heterodimers with cdks leading to an activation of Cdks by
conformational change [54, 80].
Cell cycleisunderthe controlofotherfactors,implicated
in the regulation of cell cycle transition. These regulatory
mechanisms form checkpoints where the cell cycle can be
stopped after cellular damage in order to allow repair and
to maintain cellular integrity or, alternatively, to eliminate
mutated and potentially dangerous cells. The INK4 family
(p16, p15, p18, and p19) and the Cip/Kip family (p21, p27,
and p57) [54, 80, 81] are key regulators of G1/S transition.
For example, after DNA damage, p53, a tumor suppres-
sor gene, activates transcription of p21, which inhibits
cyclin E phosphorylation leading to hypophosphorylation
of retinoblastoma protein (pRb) [81]. INK4 family inhibits
Cdk4 and Cdk6, whereas Cip/Kip family inhibits all Cdks.
Retinoblastoma protein needs to be phosphorylated in order
to release transcription factor E2F activating genes involved
in the S phase-like PCNA (proliferating cell nuclear antigen)
[82]. p53 is also important for the regulation of the G2/M
transition, which requires activation of the cyclin B-cdk2
complex.Thiscomplexaccumulatesduringthepreviousstep
of the cell cycle but is inactivated by a phosphorylation
at tyrosine 15 and threonine 14 by Wee 1 and Myt 1.
These phosphate groups are removed by the phosphatase
CDC25A when cells enter mitosis. In the case of DNA
damages, p53 is activated and increases the level of p21
that is directly inhibiting cdk2. Moreover, 14-3-3 protein,
a transcriptional target of p53, leads to a sequestration of
cdk2 in the cytoplasm [83]. Other mechanisms involved in
the regulation of the G2 checkpoint or the mitotic spindle
checkpoint are reviewed by Stewart et al. [54].
Cancer cells are characterized by deregulation of the cell
cycle via alteration of cell cycle controllers (cyclins) and cell
cycle regulators (p53) [54], resulting in a perturbation of cell
cycle checkpoints.
Currently,thereisevidencethatprostaglandinsproduced
by COX-2 intervene in tumor cell proliferation as NSAIDs
and selective COX-2 inhibitors inhibit proliferation of
diﬀerent cancer cell types expressing COX-2 [30]. NS-398,
a COX-2 speciﬁc inhibitor, was described to reduce cell
proliferation of MC-26 cell line, a highly invasive mouse
CRC cell model expressing constitutively COX-2 [8]. This
eﬀect was associated with a reduction of cyclin D level, a
key protein involved in G1-S transition [54], and PCNA,
thus increasing the processivity of DNA polymerase [82].
NS-398 and COX-2 speciﬁc inhibitor nabumetone reduced
cell proliferation of U937 (acute promonocytic leukemia)
and ML1 (human myeloblastic leukemia), thus leading to an
accumulation in G0/G1 phase [33]. Interestingly, meloxicam
was also able to downregulate PCNA and cyclin A in HepG2
cell line (hepatocellular carcinoma cells), leading to an
inhibition of the cell proliferation and an accumulation of
the cells in G0/G1 phase of cell cycle [84]. Alternatively,
the link between COX-2 and CRC has been demonstrated
by the fact that prostaglandin E2 (PGE2) derivating from
COX-2-mediated arachidonic acid metabolism increased the
proliferation of colorectal cancer cells [85].
The inhibitory eﬀect of NSAIDs on cell proliferation
of CRC has been also observed in ovarian cancer. Indeed,
treatment of OVCAR-3 tumors xenotransplanted in nu/nu
mice (nude mice) with aspirin and piroxicam (NSAIDs) and
the selective COX-2 inhibitor meloxicam led to a reduction
of tumor growth [86].
It has been estimated that 40% of breast cancers show
an overexpression of COX-2, which is associated with a bad
prognosis [5]. Indomethacin (NSAIDs), celecoxib, rofecoxib
andnimesulidehavebeenshowntoabletoinhibit cellprolif-
eration of these cells [5]. Moreover, prostaglandins were able
to increase cell proliferation of hormonal-dependent breast
cancer by increasing transcription of CYP19 aromatase
implicated in estrogen biosynthesis [87].
Several studies revealed that inhibition of COX-2 by
celecoxib in Burkitt’s lymphoma cell lines RAJI, BjAB,
(Epstein-Barr virusnegative), and BL41 led to a reduction
of cell proliferation [34]. NS-398 and celecoxib were able to
reduce proliferation of pancreatic cancer cell line, Panc-1 in
a dose-dependent manner [88]. Treatment with celecoxib of
these cells implanted into nude mice led to a reduction ofInternational Journal of Cell Biology 7
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Figure 3: Eﬀects of COX-2 inhibitors on cell proliferation. Cell cycle is divided into diﬀerent steps: G1, S, G2, and M (mitosis). This process
is regulated by cyclin proteins, which activate cyclin-dependent kinase (cdk) and phosphatase (i.e., CDC25) or kinase like cyclin-dependent
kinase inhibitors such as p16, p15, p18, p19, p21, and p27 [54]. Selective COX-2 inhibitors are able to modulate some cell cycle checkpoints.
In this picture, some examples of this link have been shown for diﬀerent cell types: MC26, colorectal cancer; HepG2, hepatocellular
carcinoma; K562, chronic myeloid leukemia. Cdk; cyclin-dependent kinase; pRb, retinoblastoma protein; PCNA, proliferating cell nuclear
antigen.
the volume of the tumor [88]. Other studies have shown that
celecoxib is able to reduce cell proliferation of the chronic
myeloid leukemia (CML) cell line K562, which expresses
COX-2 at the mRNA and protein level [89]. This eﬀect
was accompanied by an accumulation of cells in G0/G1.
Moreover, the inhibition of cell proliferation was correlated
to a downregulation of cyclin D1, cyclin E, and pRb and the
upregulation of p16 and p27 [89]. Similar results were found
on this cell type with the other selective COX-2 inhibitor
DUP-697 [77]. Diﬀerent eﬀects are recapitulated in Figure 3.
5. Implication of COX-2 in Cell Death
5.1. Apoptosis. Apoptosis (type I cell death) is important
for the development and maintenance of tissue homeostasis
of multicellular organisms [90, 91]. This active form of
cell death is characterized by the occurrence of typical
cell alterations including plasma membrane blebbing, cell
shrinkage, chromatin condensation and nuclear fragmen-
tation, and, ﬁnally, formation of apoptotic bodies, which
can be phagocyted by macrophages [92]. Deregulation of
apoptosis is linked to several pathophysiological disorders,
including autoimmune disorders, Alzheimer’s disease, and
cancer [93].
Two major cascades of intracellular events are commonly
involved in mediating apoptosis (Figure 4). The intrinsic
pathway, also called the mitochondrial or stress-induced
apoptotic pathway, is activated in response to damaging
stresses,suchasDNAdamage.Typicalhallmarksofthispath-
way are mitochondrial outer membrane permeabilization
(MOMP), accompanied by a collapse of the mitochondrial
membrane potential [51]. These events lead to the release
of cytochrome c into the cytosol, which is an indispensable
component of the apoptosome, the death complex formed
also by APAF-1, and procaspase-9. Once recruited, this
proteaseiscleavedtoitsactivatedform(caspase-9)tofurther
activate the executor caspase-3 and, ﬁnally, to ﬁnalize the
apoptotic program.
Alternatively, the extrinsic, or physiological, apoptotic
pathway (Figure 4) can be triggered upon binding of speciﬁc
ligands to death receptors characterized by the presence of
a death eﬀector domain [94]. Ligands include cytokines,
such as TNFα, tumor necrosis factor-related apoptosis-
inducing ligand-induced apoptosis (TRAIL), or FAS. After
binding,deathinducingsilencingcomplex(DISC)isformed.
The DISC is composed by the adaptors proteins TRADD
(TNF receptor-associated death domain) and FADD (Fas-
associated death domain) and is able to recruit and activate
pro-caspase-8. Finally, caspase-8 activates caspase-3 in order
to trigger the ﬁnal steps of apoptosis (Figure 4).
Cross-talks between the two pathways take place. The
extrinsic apoptotic pathway can activate the intrinsic8 International Journal of Cell Biology
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pathway via truncation of the BH3-only protein Bid (t-
Bid) by caspase-8. t-Bid interacts with mitochondria, by
favoring the activation of the proapoptotic Bcl-2 family
members Bak and Bax, thus leading to MOMP and caspase-
9a c t i v a t i o n[ 51, 95]( Figure 4). The intrinsic apoptotic
pathway may, in turn, activate caspase-8, downstream to
caspase-3[96](Figure 4).Cross-talksrepresentanimportant
strategy of ampliﬁcation loops carried out by dying cells to
ensure/potentiate cell death.
5.1.1. Involvement of COX-2 in Intrinsic Apoptosis. When
cells are damaged by a variety of chemicals or physical stress
(i.e., reactive oxygen species, UV, and ionizing radiation),
they undergo apoptosis by triggering the intrinsic apoptotic
pathway (Figure 4). This pathway may be associated with a
redox disequilibrium, mediated by depletion of glutathione
(GSH)[94,97,98],requiredfortheactivationandtransloca-
tiontomitochondriaoftheBcl-2pro-apoptoticmemberBax
[98], which, in turn, forms complexes (oligomers) mediating
MOMP and cytochrome c release. As Bax, Bak may play the
same role [99]. In contrast to Bax, Bak is already present
at the surface of mitochondria, normally sequestered in its
activemonomericformbytheBcl-2anti-apoptoticmembers
Bcl-xL and Mcl-1 (see Burlacu for a general overview of
the Bcl-2 family members modulation involved in Bax/Bak
activation [51]).
Apoptosis is regulated in order to maintain tissue home-
ostasis. This regulation implicates protein-protein inter-
actions, with some of them counteracting apoptosis. In
this view, the interaction between Bcl-2 family pro- and
antiapoptotic members represents a crucial and delicate step.
Bcl-2 is the best described member of this family preventing
Bax activation [51]. Bax can form also a complex with the
anti-apoptotic protein Bcl-xL [53] and Mcl-1 [14]. Similarly,
Bakactivityismonitoredbytheanti-apoptoticmembersBcl-
xL and Mcl-1 [51]. The interaction between Bax/Bak and the
Bcl-2familyanti-apoptoticmembersiscarefullyregulatedby
the BH-3-only proteins. Another carefully regulated down-
stream checkpoint of the apoptotic pathway is the activation
of caspases. Inhibitor of apoptosis (IAP) family, by directlyInternational Journal of Cell Biology 9
interacting with caspases (i.e., XIAP, survivin [100]) controls
and prevents their activity once cleaved. IAPs monitoring
function can be, in turn, counteracted by the pro-apoptotic
SMAC/DIABLO, a mitochondrial heterodimer, which is
released from mitochondria when MOMP is aﬀected [101].
This interaction favors the induction of apoptosis.
Imbalance between cell proliferation and apoptosis
observed in cancer can be tightly related to an altered
function of pro-apoptotic proteins as well as to an up-
regulation of anti-apoptotic proteins (i.e., Bcl-2 or IAPs)
or a downregulation of tumor suppressor genes (i.e., p53).
In addition, the activation of prosurvival pathways (i.e.,
PI3K/Akt) may be implicated upstream. Inﬂammation can
contribute to this imbalance via cytokines secreted in the
tumor microenvironment able to activate survival path-
ways. For example, TNFα can induce NFκB, leading to
an inhibition of apoptosis [38]. COX-2 seems also to play
a role in this process because it is known that COX-2
inhibition is correlated to an increase of apoptosis in several
cancermodels.NS-398downregulatedBcl-2expressioninan
androgen-sensitive human prostate cancer cell line LNCaP
that exhibited a high constitutive level of COX-2 [102].
Similar results have been observed in human colorectal
cancer cells (HCA-7 cell line which expresses COX-2) where
PGE2 was able to inhibit apoptosis induced by SC58125,
a selective COX-2 inhibitor, and increase Bcl-2 expression
[46]. Diﬀerent mechanisms are supposed to explain how
COX-2 inhibitors may trigger apoptosis. In a number of
studies, COX-2 inhibition was linked to a concomitant
increase of intracellular arachidonic acid. In HT-29 human
colon adenocarcinoma cell this accumulation led to the
induction of apoptosis [103]. The arachidonic acid-induced
apoptosis was inhibited by Bcl-2 transfection, indicating
a role of arachidonic acid in aﬀecting Bcl-2 intracellular
levels [103]. Accumulation of arachidonic acid can aﬀect
apoptosis by mediating an increase of pro-apoptotic intra-
cellular ceramides caused by activation of sphingomyelinase
[104, 105]. Sulindac sulphide, a metabolite of sulindac, also
activates sphingomyelinase and enhances the ceramide level
in the two human colorectal carcinoma cell lines HCT116
and SW480 [106].
COX-2 reduces pro-apoptotic nitric oxide (NO) levels in
cancer cells downstream of prostaglandin production [30]
(see Br¨ une et al. [107] for an overview on nitric oxide role
in apoptosis). Chang et al. reported that PGE2 prevented
apoptosis induced by NGF (nerve growth factor) withdrawal
by increasing the level of dynein light chain, an inhibitor
of neuronal NO synthase in pheochromocytoma of the
rat adrenal medulla PC12 cells, thus leading to decreased
intracellular NO levels [108].
More recently, connections between COX-2 inhibitors
and p53 family members have been described. For example,
celecoxibwasshowntoabletomodulatediﬀerentisoformsof
p73, a p53 family member in neuroblastoma cell lines [109].
p73 encodes many isoforms with diﬀerent roles. Tap73 is
pro-apoptotic and contains a transactivation domain. This
isoform is considered as a tumor suppressor gene because
i ts e e m st ob ei n v o l v e di nc e l lc y c l er e g u l a t i o na sw e l la s
in apoptosis induction [109, 110]. In contrast, DeltaNp73
is anti-apoptotic and lacks the transactivation domain.
DeltaNp73 is overexpressed in neuroblastoma, leading to
chemotherapy resistance [109]. It has been shown that
celecoxib was able to upregulate Tap73 and downregulate
DeltaNp73.ThesedatasuggesttheuseofCOX-2inhibitorsas
p73 modulators in order to improve eﬃciency of chemother-
apy [110].
The apoptotic eﬀect of COX-2 inhibitors has been also
observed for other tumor cell types, such as in the chronic
myeloid leukemia model K562 where DUP-697 induced
apoptosis by cell cycle arrest and caspase-8 activation [77].
COX-2 inhibitors can also activate prosurvival pathways.
The PI3K/Akt pathway is a survival pathway, frequently
activated in cancer cells [49]. PI3K produces PIP3 (phos-
phatidylinositol 3,4,5 triphosphate) that activates PDK1
(pyruvate deshydrogenase kinase). This protein phosphory-
lates and activates PKB (protein kinase B), which, in turn, is
responsibleforthephosphorylationofseveraltargetsplaying
a modulator function in apoptosis. An anti-cancer eﬀect of
celecoxib due to the inhibition of Akt signaling [111]w a s
observed in a gastric cancer model. Celecoxib triggered also
apoptosis in osteosarcoma cells (MG-63) through down-
regulation of Bcl-2, survivin and PI3K (phosphoinositide 3-
kinase) pathway [112]. Similarly, Hsu et al. [113] found that
inhibition of Akt phosphorylation by celecoxib in prostate
cancer models (LNCaP and PC3 cell lines which express
constitutively COX-2) led to apoptosis, but in this case
without aﬀecting Bcl-2 level.
The PI3K pathway is negatively regulated by PTEN
(phosphatase and TENsin homolog), which converts PIP3
in PIP2, preventing PKB activation and Bad phosphory-
lation/sequestration. Thus PTEN is considered as a tumor
suppressor gene. It has been shown that NS-398 was able to
increase the level of PTEN in human gastric carcinoma cell
line MKN45 [114].
One of the PKB targets is Bad, a BH3-only member [51].
The nonphosphorylated form of Bad plays a pro-apoptotic
role, by binding Bcl-xL or Bcl-2 and, thus, preventing their
interactions with Bak and Bax. The activation of PI3K/Akt
pathway may lead to the phosphorylation of Bad, which
is consequently sequestrated in the cytoplasm by 14-3-
3 protein and, in this way, inhibited in its pro-apoptotic
function [51]. It has been reported that sulindac sulphone,
indomethacine, and SC-236 were able to induce apoptosis
via Bad activation, by inhibiting 14-3-3 expression in a
dose- and time-dependent manner in HT-29 cells [115].
This eﬀect was tightly related to PPARδ. It is known,
indeed, that 14-3-3 protein contains PPRE recognized and
bound by PPARδ [115]. COX-2 can mediate the synthesis of
prostaglandin I2, which can bind and activate PPARδ [41].
Thus, it has been suggested that the inhibition of COX-2,
leading to a decrease of PGI2, impaired PPARδ activation,
which, in turn, was responsible for a downregulation of
14-3-3 protein, thus allowing Bad to play its pro-apoptotic
functions [115].
NFκB is a most important transcription factor involved
in survival by enhancing transcription of anti-apoptotic
proteins such as Bcl-2 [14, 15]. Sulindac inhibits NFκBi n
two colon cancer cell lines (human colon adenocarcinoma10 International Journal of Cell Biology
HCT-15 and HT29 cell lines) [116]. Similar results were
obtained with diclofenac, which was able to inhibit nuclear
accumulation of NFκB[ 117]. In the same study, PGE2 was
demonstratedtoincreasethetranscriptionalactivityofNFκB
p65/p50 dimer in CACO-2 cells (human epithelial colorectal
adenocarcinoma cells), transfected with a luciferase con-
struct containing NFκB response elements [117].
It is known that activation of prostaglandin receptors
induces an increased cAMP level which in turn can activate
protein kinase A (PKA) [58]. Studies have suggested that
PKA, like PKB, phosphorylates Bad [118], leading to its
sequestration and inhibition of apoptosis. Some of the pro-
or anti-apoptotic mediators aﬀected by COX-2 inhibitors are
schematized in Figure 4.
5.1.2. Implication of COX-2 in Extrinsic Apoptotic Cell Signal-
ing Mechanisms. Studies reported that COX-2 inhibitors are
also associated with a sensitization of tumor cells to extrinsic
apoptosis. Thus, DUP-697 sensitized HT29 colon cancer
cell line to TRAIL-induced apoptosis. This eﬀect was due
to an accumulation of arachidonic acid inside the cells,
which activates sphingomyelinase, triggering a clustering of
d e a t hr e c e p t o r( D R )5r e c e p t o r si nc e ra m i d ea n dc h o l e s t e r o l -
rich domains [119]. Alternatively, the expression of COX-
2 has been frequently associated with a modulation of the
expression of death receptors, thus leading to an upstream
control of the extrinsic apoptotic pathway. Tang et al. [120]
showed that COX-2 overexpression in human colon cancers
cells led to an inhibition of DR5 expression and a resistance
to TRAIL-induced apoptosis. Accordingly, COX-2 speciﬁc
inhibitors, NS-398 and CAY10404, are sensitizing human
hepatocarcinoma cells (SK-Hep1 and HLE) to TRAIL-
induced apoptosis. This eﬀe c tw a sd u et oa nu p r e g u l a t i o n
of TRAIL receptors (TRAIL R2/DR5 and TRAIL-R1/DR4),
together with an ability of the compounds to induce a down-
regulation of the anti-apoptotic proteins survivin (IAP) and
Bcl-xL [121]. In hepatocellular carcinoma models (HepG2,
Bel7402, and SMMC-7402), Li et al. [84] showed that COX-
2 inhibition with meloxicam led to an upregulation of Fas-
mediated apoptosis. In vivo studies performed on transgenic
mice constitutively expressing human COX-2 conﬁrmed an
increased resistance to Fas-induced apoptosis in liver, as
shown by the preservation of liver architecture in COX-
2-expressing mice compared to wild type [122]. Similarly,
another study performed on human extrahepatic bile duct
carcinoma cell line showed that COX-2 induction led to the
inhibition of Fas-induced apoptosis, whereas the inhibition
of COX-2 with NS-398 in cytokine-treated cells exacerbated
apoptosis induced by CH-11, an agonist of Fas receptor
[123].
AKT pro-survival pathway may play a role also in
the modulation of extrinsic apoptosis. The human gastric
carcinoma cell line MKN45, which expresses COX-2, was
sensitized to Fas-induced apoptosis by NS-398. The COX-
2 inhibitor, indeed, was able to increase the level of PTEN,
leading to a decrease of Akt phosphorylation and activation
of Bad [114]. Some eﬀects of COX-2 inhibitors on extrinsic
apoptosis are summarized in Figure 4.
Altogether, these results encourage the perspective that
COX-2 inhibitors could be used in future as a therapeutic
strategy to sensitize tumor cells to apoptosis induced by
physiological stimuli.
5.2. Involvement of COX-2 in Other Types of Cell Death
5.2.1.Anoikis. Anoikisisaformofapoptosismediatedbythe
loss of cell anchorage. This pathway plays a fundamental role
during development and maintenance of tissue homeostasis
by killing damaged cells or detached cells in order to main-
tain tissue architecture. For example, the inner endodermal
cellsundergoanoikisafterthelossofanchoragetothematrix
during development [124]. It is known also that intestinal
epithelial cells loose anchorage when located at the luminal
surface, leading to anoikis [42]. As a form of apoptosis,
anoikis is dependent on caspase activation and cytochrome
c release by mitochondria and is regulated by Bcl-2 family
members [42].
It has been shown that anoikis is prevented in cancer
cells, thus favoring tumor progression with the formation
of metastasis [42]. Accordingly, modulation of anoikis is
considered a promising target for anti-cancer strategies.
Cell anchorage is due to cell-cell and cell-matrix interac-
tions. Cell-cell interactions are mainly mediated by integrins
which are transmembrane receptors located at the cell
surface and composed of alpha and beta chains [125]. Many
intracellular signals can act downstream to integrins, which,
correctly switched on, can ensure cell survival. Some of them
are mediated by kinases such as Focal-adhesion-kinase (Fak)
or integrin-linked kinase (ILK) [42]. Fak is phosphorylated
upon integrin adhesion, leading to activation of other sig-
naling pathways like PI3K, MAPK. ILK is a serine/threonine
kinase that directly phosphorylates PKB.
Together with cell-cell and cell-matrix interactions, para-
crinefactorscouldbeimportantfortheregulationofanoikis.
It has been shown that E-cadherin (epithelial cadherin)
can activate COX-2 [23]. It is possible that prostaglandins
produced by COX-2, which act in an autocrine and a
paracrine manner, favor cell survival. A study from Joseph et
al. [126] showed that PGE2 inhibited anoikis in IEC-18 cells
(rat intestine ileum cells). This eﬀect was suggested to be due
to cAMP signaling because prostaglandin E2 receptors are
coupled to adenylate cyclase, which converts AMP to cAMP
[126].
Other studies demonstrated that COX-2 inhibits anoikis
via activation of PI3K/Akt pathway, as the case of a human
bladder cancer cell line expressing COX-2 [40]. A link
between COX-2 and anoikis has been described, further-
more, in uterine endometrial carcinoma [127]. COX-2 is
over-expressed in this type of cancer and this is associated
with tumor aggressiveness. In addition, a recent report based
on HEC-1B and RL95-2 (two human endometrial cancer
cell lines) showed that the treatment of these cells with
hepatocyte growth factor (HGF) led to an up-regulation of
COX-2. Hepatocyte growth factor interacts with its tyrosine
kinase receptor c-Met. This interaction is responsible for
tumor progression. Overexpression of HGF/c-Met has been
described in diﬀerent tumors such as breast cancer [128]International Journal of Cell Biology 11
as well as head and neck cancer [129], also in endometrial
carcinoma [130]. It has been demonstrated that HGF
inhibited anoikis and treatment of HEC-1B and RL95-2
cellswiththeCOX-2selectiveinhibitormeloxicamprevented
HGF-mediated anoikis resistance [127]. Similar results were
obtained in head and neck squamous cell carcinoma [131].
Altogether these data suggest that COX-2 may be impli-
cated in the inhibition of anoikis and that COX-2 inhibitors
may play a role in inhibiting tumor progression (metastasis),
by sensitizing tumor cell to anoikis.
5.2.2. Autophagy. Autophagy is a process triggering cells
to degrade intracellular constituents, ranging from proteins
up to entire organelles. It represents an important process
ensuring the turnover of long-lived cellular components,
which can be activated also by stress conditions like nutrient
starvation in order to avoid cell death. The process starts
with the formation of doubled membrane-bound vacuoles
corresponding to autophagosomes that entrap parts of the
cytoplasm or organelles (i.e., mitochondria). Then, these
structures are fused with lysosomes (autolysosomes), thus
leading to the degradation of the intracellular parts previ-
ously enclosed. Together with apoptosis, when exacerbated,
autophagy contributes to the modulation of homeostasis, by
eliminating damaged and potentially dangerous cells (type II
cell death) [132]. However, the relationship between apopto-
sis and autophagy is currently still poorly understood [132]
because in some cases autophagy permits an adaptation of
the cells to stress (i.e., nutrient starvation), thus counteract-
ing apoptosis, whereas, in other cases, autophagy is a process
triggering downstream apoptosis [132]. Indeed, similar
stimuli can induce both apoptosis or autophagy [132].
This process is implicated in pathologies such as Alz-
heimer’s disease and cancer, suggesting a promising ﬁeld in
therapy. By considering that COX-2 is supposed to play a
roleinapoptosisandalinkbetweenapoptosisandautophagy
exists, it is conceivable that COX-2 plays a role also in this
process. Currently, not many studies aimed at investigating
a possible link between COX-2 and autophagy have been
published. Nevertheless, one study revealed that sulindac
sulphide (NSAIDs) induced apoptosis of the colon cancer
HT29 cell line. This eﬀect was increased by treatment of
the cells with 3 methyl-adenine, a well-known inhibitor
of autophagy [133]. Moreover, the extent of apoptosis in
Q204L cells (a clone of HT-29 cells in which 3 methyl-
adenine-sensitive autophagic sequestration is impaired) was
less than in HT29. These data suggest that autophagy can
delay sulindac sulphide-induced apoptosis [133].
6. COX-2 Inhibitors in Cancer Therapy
Despite the latest progress in cancer research and the diﬀer-
ent strategies to kill cancer cells, several tumors are resistant
to conventional therapeutics treatment (i.e., radiotherapy,
chemotherapy, and photodynamic therapy).
COX-2 inhibitors play an important role in cancer
prevention. Indeed, the chronic intake of NSAIDs is able
to consistently reduce the appearance and incidence of
many types of cancer as described in Familial Adenomatous
Polyposis (for celecoxib) [134, 135] and also in breast cancer
[136]. This property of COX-2 inhibitors could be useful for
patients with a high risk to develop cancer such as people
with Li-Fraumeni syndrome, for example [137]. The fact
that many reports in literature suggest that COX-2 inhibitors
are responsible for an inhibition of cell proliferation and
apoptosis induction in a number of diﬀerent cancer cell
models prompts to consider a possible use of COX-2
inhibitors in future therapeutical protocols, administered
alone as well as in combination with anti-cancer clinical
protocols in order to improve tumor cell death.
6.1. COX-2 Inhibitors in Combination with Radiotherapy.
Radiation therapy is a common treatment used for the
treatmentofsolidtumors,suchasbreast,prostate,colorectal,
and lung cancers. It is known that the anti-cancer properties
of ionizing radiation are due to pleiotropic mechanisms.
Radiation leads to the formation of DNA doubled-strand
breaks in proliferating cells, which triggers the activation of
DNA damage pathways (i.e., p53), followed by the induction
of apoptosis [36]. The importance of Bcl-2 family members
during apoptosis [51] suggests that prosurvival proteins (i.e.,
Bcl-2, Bcl-xL) play an important role in radioprotection of
tumor cells. The NFκB pathway seems to be implicated,
being required in regulating expression of the anti-apoptotic
Bcl-2 family members like Bcl-xL [36]. Moreover, it is well
established that NFκB regulates the level of COX-2, suggest-
ing that COX-2 may play a role in radiotherapy resistance
[21].Similarly,nimesulidecouldincreaseradiationeﬃciency
in nonsmall cell lung cancer in vivo (nude mice) and in
vitro (A549 cell line) as shown by Grimes et al. [138]. This
eﬀect was due to a down-regulation of MnSOD (superoxide
dismutase containing manganese (Mn) and localized in
mitochondria), a primary antioxidant protein and survivin,
an anti-apoptotic protein (IAPS family member). These two
proteins are regulated by NFκB. It is well known that during
radiation therapy NFκB can be upregulated due to reactive
oxygen species release and inﬂammation (i.e., PGE2). This
report suggests that nimesulide may act on NFκB to inhibit
MnSOD and survivin.
Melanoma is known to be very resistant to conven-
tional radiotherapy and chemotherapy. Irradiation of two
melanoma cell lines WM35 and LU1205 in the presence of
NS-398,aselectiveCOX-2inhibitor,stronglyexacerbatedthe
G2/M arrest as well as the induction in apoptosis. Accord-
ingly, the down-regulation of COX-2 by RNA interference in
these cell lines was followed by an upregulation of p53 and
G2/M arrest [36], thus conﬁrming that the eﬀect of NS-398
is due to its role on COX-2 inhibition.
OtherstudieshaveshownthattheradiosensitivityofPC3
(human prostate carcinoma cells) and Hela (human cervical
carcinoma cells) was enhanced after silencing of COX-2 by
siRNA. NS-398 was able to increase radiosensitivity of PC3
cells expressing COX-2, but not in PC3 silenced for COX-2.
In contrast, NS-398 enhanced radiosensitivity of Hela cells,
irrespective to the level of COX-2 [37].
However, combination of COX-2 inhibitors with radi-
ation therapy can also lead to a reduction of eﬃciency of
the radiotherapy. In one report, it has been shown that the12 International Journal of Cell Biology
selective COX-2 inhibitor nimesulide decreased radiation
eﬃciency of two head-and-neck cancer cells lines (SCC9 and
SCC25) which are COX-2 positive [139]. This suggests that
thesensitizationoftumorcellstoradiationmightbestrongly
dependent on tumor cell type.
6.2. COX-2 Inhibitors in Combination with Chemotherapy.
Many types of cancer are treated with chemotherapeutic
agents leading to inhibition of cell proliferation or induction
of apoptosis [140].
One of the major causes of chemotherapy failure is the
survival and/or development of multidrug resistant cancer
cells. This resistance is mediated by many mechanisms
including over-expression of proteins involved in inhibition
of apoptosis (i.e, Bcl-2), leading to insensitivity of tumor
cells to apoptotic stimuli; an up-regulation of DNA repair;
alteration of the target; up-regulation of detoxiﬁcation
enzymes (i.e., Glutathione S-transferases); and extrusion of
chemotherapeutic drugs by overexpression of ATP-binding
cassette family proteins, such as MRP (multidrug resistant-
associatedprotein)BCRP(breastcancerresistanceproteinor
mitoxantrone resistance protein) because these proteins reg-
ulateabsorption,distribution,andexcretionofvariousphar-
macologic compounds [141]. Consequently, the chemother-
apeutic agents are immediately extruded from the cells. P-gp
(P-glycoprotein) is one of the best-understood mechanisms
leading to multidrug resistance (MDR). Tremendous eﬀorts
have been made to ﬁnd solutions to overcome MDR.
Recently, COX-2 inhibitors showed an ability to sensitize
tumor cells to chemotherapeutic agents in several models
and also in clinical assays. Colorectal cancers are particularly
aﬀected by chemoresistance. One study revealed that the
COXs inhibitors naproxen and indomethacin heptyl ester
were able to downregulate P-glycoprotein in human colorec-
t a lC A C O - 2c e l ll i n e .[ 39]. Indomethacin inhibited the activ-
ity of the protein and aﬀected COX-2 mRNA and protein
level [39]. Another study showed that meloxicam was able
to downregulate MDR1 in HL60 (a human promyelocytic
leukemia) cell line as well as in acute myeloid leukemic blasts
[142]. The regulation of MDR1 by COX-2 has been also
suggested in another study [143] in which it was reported
that transfection of COX-2 cDNA with adenovirus in renal
rat mesangial cells led to an upregulation of MDR1 gene.
The combination of COX-2 inhibitors with chemotherapy
was also assayed in a study in which the sensitivity of a
humangastriccancercelllineMKN45tocisplatin(alkylating
agent) resulted increased by COX-2 downregulation with
siRNA [35], suggesting a possible therapeutic application of
this combination. Similarly, the sensitivity to cisplatin was
increased by celecoxib in a human osteosarcoma cell line
(MG-63) and this eﬀect was linked to a down-regulation of
anti-apoptotic proteins survivin, Bcl-2, and an inhibition of
the survival pathway PI3K/Akt [112]. It was also reported
that B-CLL (B chronic lymphoid leukemia) overexpressed
COX-2 and the combination of NS398 with chlorambucil,
an alkylating agent, increased the level of apoptosis in B-
CLL blasts coming from patients [32]. Moreover, several
lymphoma cell lines overexpressed COX-2, such as RAJI,
BJAB, BL41 and treatment of these cells with celecoxib led to
a decrease of cell proliferation in a dose-dependent manner
[34].
NS-398 was able to increase the cytotoxicity of gemc-
itabine, an analog of the antimetabolite nucleoside deoxycy-
tidine, used for treatment of nonsmall cell lung carcinoma,
in A549ACA cell line (lung adenocarcinoma cell line) by
enhancing apoptosis [144]. The combination of NS-398 and
gemcitabine is also associated with an inhibition of cell
proliferation with an accumulation of the cells in G0/G1
phase of cell cycle and an increase of p21 [144].
All of these data suggest that COX-2 is implicated in
anti-apoptotic and MDR pathways and that selective COX-2
inhibitorscouldbeusedtoimprovechemotherapyeﬃciency.
6.3. COX-2 Inhibitors in Combination with Photodynamic
Therapy. An alternative therapeutic approach to treat can-
cers is photodynamic therapy. This procedure is particularly
used for such solid tumors including skin, bladder, and
head and neck cancers in addition to other diseases like
age-related macular degeneration and psoriasis [145]. The
treatment consists in the administration of a photosensitizer,
a molecule that selectively accumulates in tumors and
is activated by light (600–850nm). The photosensitizers
may accumulate in diﬀerent compartments of tumor cells
like mitochondria (i.e., porphycene monomer), nucleus,
lysosomes (i.e., lysyl chlorin p6), and plasma membrane
(i.e., monocationic porphyrin like Photofrin). Then, the
photosensitizer is excited with a laser from a single state to a
triplet state. The triplet-state photosensitizer is implicated in
two oxygen-dependent reactions. In the ﬁrst one, the triplet
canreactwithcellmembraneormolecules,leadingtoradical
formation, which in combination with oxygen produce
oxygenated products, cytotoxic for the cells [146, 147]. In the
second reaction, the triplet-state photosensitizer can transfer
its energy directly to oxygen in order to produce singlet
oxygen (102), which is known to be a very highly reactive
oxygen species and is implicated in cell damage. Therefore,
this therapy leads to tumor destruction due to cell death
occurring via apoptosis and necrosis. Vasculature damages
and activation of immune response aretwo important eﬀects
implicated in tumor ablation.
SomeparametersaﬀectPDTeﬃciency,suchasthedistri-
bution of the photosensitizer, photobleaching, hypoxia/ano-
xia, and the vascularization of the tumor [146]. The main
reason of failure of this therapeutic approach is linked to
an up-regulation of angiogenic and inﬂammatory factors
in the tumor microenvironment that strongly reduces the
PTD eﬃciency with a consequent tumor relapse. The link
between inﬂammation and survival pathway activation,
cell proliferation, and angiogenesis is well known and
contributes to tumor progression [3, 6]. It has been shown
that PDT leads to an increase of TNFα,I L 1 β, PGE2, VEGF
(vascular endothelial growth factor), and MMP9 (matrix
metalloproteinase 9) [147]. These molecules can counteract
tumor responses to PTD by promoting cell proliferation and
cell survival [38].Interestingly,ithasbeendemonstratedthat
COX-2 is upregulated during PDT treatment in diﬀerent
cancer models. As for radiotherapy and chemotherapy,International Journal of Cell Biology 13
this suggests COX-2 as a possible target to increase PDT
eﬃciency.
Indeed,celecoxibhasbeenprovedtoaﬀectthePhotofrin-
induced PDT in in vitro and in vivo studies performed
on a mouse mammary carcinoma BA cell line [148]. In
vitro,celecoxibandNS-398increasePDT-inducedapoptosis.
These results were correlated with caspase-3 and PARP
cleavage and Bcl-2 degradation. In vivo, the photosensi-
tization by COX-2 inhibitors was not due to apoptosis
exacerbation. Interestingly, celecoxib and NS-398 decrease
PDT-induced apoptosis but were also able to decrease the
level of angiogenic factors such as TNFα,I L 1 β, PGE2, VEGF,
and MMP9 [148].
Upon chlorin-induced PDT, COX-2 was found up-regu-
lated 25-fold in mouse mammary carcinoma RIF cells
[149]. This up-regulation was associated with an increase
of PGE2 level in the tumor microenvironment. When
RIF cells were transplanted in CH3/HeJ mice, for in vivo
studies, PDT similarly induced an increase of COX-2 and
PGE2. These eﬀects were prevented by NS-398. Here, it was
demonstrated that PDT induced vascular endothelial growth
factorexpression(VEGF)andthisincreasewasattenuatedby
treating mice with NS-398, meaning that COX-2 might play
a role also in angiogenesis. In consequence of these eﬀects,
the combination of COX-2 inhibitors with PDT resulted in
an increased eﬃciency of tumor treatment.
Possible correlation between COX-2 level and resistance
to PDT has been also investigated in Hela (human cervix
carcinomacells)andT24(humantransitionalcellcarcinoma
of the urinary bladder) cells [150]. It has been reported
that in PDT induced by hypericin, a natural photosensitizer
which accumulates in endoplasmic reticulum and Golgi
apparatus, an increase of PGE2 levels occurred. Hypericin
induces apoptosis by triggering the release of cytochrome
c after light excitation through a process requiring the
activation of p38 MAPK, which it is known to induce an
up-regulation of COX-2 [23, 151]. The increase in PGE2
levels was prevented by the use of a p38 MAPK inhibitor
(PD169316). Moreover, the impairment of p38 MAPK was
associated with an increase in the susceptibility of tumor
cells to PDT. However, COX-2 inhibitors did not lead to the
same eﬀect, meaning that COX-2 was not involved in PDT
resistance in this model.
In contrast to the study of Ferrario et al. [148, 149],
a report from Makowski et al. [152] has revealed that
rofecoxib, NS-398, and nimesulide were unable to potentiate
PDT in C-26 cells (poorly diﬀerentiated colon adenocarci-
noma cell line) in vitro. However, chronic exposition of mice
bearingC-26cellstonimesulidepotentiatedPDT.Thesedata
suggestthatCOX-2inhibitorsmayindirectlypotentiatePDT.
It is known that vasculature damages are important
for PDT eﬃciency and that COX-2 inhibitors act as anti-
angiogenic factors [153]. It has been hypothesized that these
antiangiogenic eﬀects could be responsible for the anti-
tumor eﬀect.
Currently, the link between COX-2 and PDT eﬃciency
is not well characterized. Some studies have revealed an
improvement of eﬃciency with COX-2 inhibitors whereas
other reports have demonstrated no direct eﬀects. In any
case,thiseﬀectmaybecell-typedependentasforchemother-
apy or radiotherapy.
7. Inhibition of COX-2 Expression by
Natural Compounds
Synthetic cyclooxygenase-2 inhibitors hold promise for can-
cerchemoprevention; however, recenttoxicity problemssug-
gest that new strategies are needed. Natural compounds with
the potential to inhibit key cell signaling pathways including
COX-2 gained much attention over the last regarding years
whether they are used alone or in combination with existing
chemotherapeutic agents.
Recently, Bhui et al. demonstrated that Bromelain, a
pharmacologically active compound present in pineapple
(Ananas cosmosus), leads to a marked inhibition of COX-2
expression and inactivation of NFκB. Bromelain treatment
induces up-regulation of p53 and Bax and subsequent
activationofcaspase-3andcaspase-9withadecreaseinBcl-2
expression[154].Furthermorebromelaininducesapoptosis-
related proteins along with inhibition of NFκB -driven COX-
2expressionbyblockingtheMAPKandAkt/proteinkinaseB
signaling in DMBA-TPA-induced mouse skin tumors [155].
Curcumin, a naturally occurring polyphenol from Cur-
cuma longa, was described to act as an antiinﬂammatory
and antiproliferative agent by causing downregulation of
COX-2 in cervical cancer. Curcumin-mediated apoptosis in
these cells is initiated by up-regulation of pro-apoptotic
Bax, AIF, release of cytochrome c, and downregulation of
anti-apoptotic Bcl-2, Bcl-xL in HeLa and SiHa cell lines.
This onset of apoptosis was accompanied by an increase in
caspase-3and-9activity,suggestingtheroleofmitochondria
in curcumin-mediated apoptotic cell death as described by
M. Singh and N. Singh [156]. Mar´ ın et al., furthermore,
concluded that curcumin inhibits NFκBa c t i v i t ya sw e l la s
the expression of its downstream target genes, and also selec-
tively induces apoptosis of melanoma cells but not normal
melanocytes[157].Inaddition,curcumin-inducedapoptosis
was also associated with the activation of caspase-3 and
caspase-9,andthedegradationofPARP.Curcumindecreased
the expression levels of COX-2 mRNA and protein without
causing signiﬁcant changes in COX-1 levels, which was
correlatedwiththeinhibitionofprostaglandinE(2)synthesis
[158]. In BV-2 microglial cells, curcumin and analogs were
shown to inhibit LPS-induced COX-2 expression; analogs
identiﬁed as more potent than curcumin in the screening
assay were also more potent than curcumin in preventing
COX-2 expression [159].
Coumarin (1,2-benzopyrone) is a naturally occurring
fragrant compound found in numerous plants and spices.
ResultsobtainedwithhumannonsmallcelllungcancerA549
cells suggest that downregulation of Bcl-xL, COX-2, and
MAP kinase pathway and up-regulation of p53, Akt, and
NFκB pathway are involved in the underlying molecular
mechanism of apoptosis induction as suggested by Goel et al.
[160].
Suh et al. concluded that the plant ﬂavonoid ﬁsetin indu-
ces apoptosis and suppresses the growth of colon cancer cells14 International Journal of Cell Biology
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Figure 5: COX-2 inhibition in cancer therapy.
by inhibition of COX-2- and Wnt/EGFR/NFκB-signaling
pathways [161].
Sulforaphane (SFN) is a biologically active compound
extracted from cruciferous vegetables, and presents potent
anti-cancer and anti-inﬂammatory activities by suppression
of NFkB-dependent genes involved in anti-apoptotic signal-
ing(IAP-1,IAP-2,XIAP,Bcl-2,andBcl-xL),cellproliferation
(c-Myc, COX-2, and cyclin D1), and metastasis (VEGF and
MMP-9) as published by Moon et al. [162].
Nontoxic apigenin can suppress anti-apoptotic pathways
involving NFκB activation including cFLIP and COX-2 exp-
ression as demonstrated by Xu et al. [88]. According to Nam
et al., DA-6034, a synthetic derivative of ﬂavonoid Eupatilin,
strongly enhanced apoptosis and inhibited the expression
of COX-2 and phospho-IKKalpha in inﬂammation-related
colon cancer models [163].
EGCG from green tea was described to attenuate the
AR, to downregulate IGF-1, to modulate COX-2 expression,
and to decrease MAPK signaling leading to the reduction
in cell proliferation and induction of apoptosis in prostate
cancer without toxicity [164]. Interestingly, combination of
EGCG and COX-2 inhibitor NS-398 enhanced cell growth
inhibition, apoptosis induction, expression of Bax, pro-
caspase-6, and pro-caspase-9, and PARP cleavage, inhibition
of PPAR gamma, and inhibition of NFκB compared with the
additive eﬀects of the two agents alone, suggesting a possible
synergism. In vivo, combination treatment with green tea
polyphenols and COX-2 inhibitor celecoxib resulted in
enhanced tumor growth inhibition, lowering of prostate-
speciﬁc antigen levels, lowering of IGF-I levels, and circu-
lating levels of serum IGF-1 binding protein-3 compared
with results of single-agent treatment. Accordingly, Adhami
et al. postulate the eﬃciency of synergistic and/or additive
eﬀects of combinatorial chemopreventive agents and further
underscore the need for rational design of human clinical
trials involving such natural compounds [165].
Pandey et al. published that butein inhibited the expres-
sion of the NFκB-regulated gene products involved in anti-
apoptosis (IAP2, Bcl-2, and Bcl-xL), proliferation (cyclin D1
andc-Myc),andinvasion(COX-2andMMP-9).Suppression
of these gene products correlated with enhancement of the
apoptosisinducedbyTNFandchemotherapeuticagents,and
inhibition of cytokine-induced cellular invasion. This group
clearly demonstrates that antitumor and anti-inﬂammatory
activitiesassignedtobuteinmaybemediatedinpartthrough
the direct inhibition of IKK, leading to the suppression of the
NFκB activation pathway [166].
Hostanska et al. used human colon COX-2-positive HT
29 and COX-2-negative HCT 116 or lung COX-2 proﬁcient
A 549 and low COX-2 expressing SW2 cells and showed that
willow bark extract BNO 1455 and its fractions inhibit the
cell growth and promote apoptosis in human colon and lung
cancer cell lines irrespective of their COX selectivity [167].
8. COX-2 Independent Effects
It is currently well known that several selective COX-2
inhibitors inhibit cell proliferation and induce apoptosis
independently of COX-2. Celecoxib is particularly known to
have these COX-2-independent eﬀects, which were reviewed
by Grosch et al. [68]. Indeed, celecoxib was able to directly
bind and inhibit PKB/Akt, which plays an important role
in cell proliferation and in apoptosis. Concerning cell cycle,
PKB is able to phosphorylate cdk inhibitors, such as p21 and
p27, leading to PCNA activation [168, 169]. Furthermore,
PKB can also activate several cyclin-cdk complexes andInternational Journal of Cell Biology 15
induce E2F factor in some cases [68], stimulating cell prolif-
eration. Besides, PKB inhibits apoptosis, by phosphorylating
the pro-apoptotic protein Bad and by inhibiting caspase-9
cleavage [51].
The COX-2-independent eﬀects concern also the extrin-
sic apoptotic pathway. Indeed, we discussed that selective
COX-2 inhibitors, such as NS-398, celecoxib, and meloxi-
cam, are able to modulate the sensitivity of several tumor
cells to Fas- and TRAIL-induced apoptosis. It has been
discussed that this modulation could be due to COX-2-
independent eﬀects. In fact, NS-398 and nimesulide were
able to promote TNF and TRAIL-induced apoptosis of D98
and H21 Hela cell lines [170]. In D98, COX-2 is inactive.
Moreover, prostaglandin E2 readdition was not able to revert
the sensitization eﬀect. In the same report, it has been shown
that NS-398 was able to promote apoptosis induced by TNF
in MCF-7 cell line (human breast adenocarcinoma cells),
which again does not express COX-2 [170].
A report from Ryan et al. [171] demonstrated that
SC58125 and CAY10404, two selective COX-2 inhibitors,
were able to decrease intracellular content of GSH in
malignant human B-cells. This eﬀect was accompanied by
an increase of reactive oxygen species production. Indeed,
GSH is the most important intracellular nonprotein thiol
antioxidantdefenseagainstfreeradicals,meaningthatitpro-
tects the cells from cellular damages. The GSH depletion was
correlatedinthisstudywithareducedsurvivalforthesecells.
The fact that many studies imply an association between
COX-2 inhibition and apoptosis induction or cell prolifera-
tion inhibition, without assessing whether COX-2 activity is
eﬀectively decreased, suggests caution in the interpretation
of the data. This is conﬁrmed by the observation that
diﬀerent COX-2 inhibitors may trigger apoptosis in the same
cancer cell model by modulating diﬀerent mechanisms. For
example, celecoxib [113] induced apoptosis by an inhibition
of Akt phosphorylation in prostate cancer cells COX-2-
positive LNCaP without aﬀecting Bcl-2 level. In contrast, a
study by Liu et al. [102] revealed that NS-398 in the same
cell line was able to induce apoptosis but down-regulation of
Bcl-2. These results suggest a possible COX-2-independent
eﬀect and strongly recommends considering in parallel other
experimentalstrategiestoascertaintheeﬀectiveroleofCOX-
2i nh u m a nm a l i g n a n c i e s[ 33], such as methodologies based
on RNA interference or antisense oligonucleotides. Studies
have already suggested these alternative methods. It has been
shown that the sensitivity of a human gastric cancer cell
line MKN45 to cisplatin (alkylating agent) was increased by
COX-2 downregulation with siRNA [35].
9. Conclusion
A number of studies suggest that COX-2 inhibition may
lead to an inhibition of cell proliferation in diﬀerent cancer
types. The fact that COX-2 inhibition may per se trigger
apoptosis of tumor cells and/or sensitize them to cytotoxic
treatments is an indication that COX-2 may be a good
target in cancer therapy, in order to improve the eﬃciency
of tumor cell death and to reduce tumor progression (see
Figure 5 for a synthesis). Accordingly, the combination of
selective COX-2 inhibitors with radiotherapy or diﬀerent
chemotherapeutics revealed a sensitization to apoptosis.
This eﬀect was also observed with several agents inducing
apoptosis in a physiological way, thus suggesting that COX-2
inhibitors used in combination with death receptors agonists
might be a novel approach to elicit apoptosis of cancer cells.
However, the fact that COX-2 inhibitors can mediate their
eﬀects by COX-2-independent mechanisms suggests caution
in the interpretation of the data.
Nowadays, selective COX-2 inhibitors have been
included in several clinical assays. Some of them eﬀectively
increase the eﬃciency of radiotherapy and chemotherapy
[172]. For example, celecoxib is in a clinical phase II assay in
combination with Paclitaxel, carboplatin, and radiotherapy
for patients with inoperable stage IIIA/B nonsmall cell lung
cancer [172]. These clinical assays conﬁrm that COX-2
inhibition may be a promising ﬁeld in cancer treatment.
However, the selective COX-2 inhibitors are responsible for
side eﬀects, including an increasing risk of cardiovascular
complications [67, 68]. It is hoped that other methods to
inhibit COX-2 will be developed. To this purpose, RNA
interference using vehicle (i.e., adenovirus) as well as natural
compounds were suggested by some studies [35, 76], as
alternative and promising strategy.
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